Clinical Trials- Gynecologic

 DISEASE SITE  TITLE  PHASE  CONTACT  LOCATION
Cervical  Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1(LVSI+) and IA2-IB1 Cervical Cancer (GOG 0278)  III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Cervical  Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation
Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early- Stage Cervical Carcinoma Following Radical Hysterectomy (RTOG 0724)
 III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Cervical  Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical
Hysterectomy and Pelvic Lymphadenectomy (GOG 0263)
 III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
 Cervical  A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
(ANZGOG 0902/GOG-0274/RTOG 1174)
 III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
 Cervical  RTOG 1203A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical

Cancer (Time-C)

 III

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or  Amy Filler-Katz
 The Nebraska Medical Center, Omaha NE
 Cervical  A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to

Chemoradiation Alone: The Outback Trial (ANZGOG 0902/GOG-0274/RTOG 1174)

 III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Pamela Nielsen
 The Nebraska Medical Center, Omaha NE
 Cervical  RTOG 0724 - Phase lll Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in

High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

 III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Amy Filler-Katz
 The Nebraska Medical Center, Omaha NE
Endometrial  A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma (GOG 0258)  III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Endometrial  A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine
Corpus (GOG 0238)
 III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
 Endometrial A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and

Paclitaxel for Optimally De-Bulked, Advanced Endometrial Carcinoma GOG 0258 (NCI Version Date: June 12, 2012)

 III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Pamela Nielsen
 The Nebraska Medical Center, Omaha NE
 Endometrial RTOG 1203A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical

Cancer (Time-C)

 III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Amy Filler-Katz
 The Nebraska Medical Center, Omaha NE
Ovarian Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or
Fallopian Tube Cancer (GOG 0273)
 III

Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939

and

Good Samaritan – Michaela Sherbeck - michaelasherbeck@catholichealth.net

Nebraska Methodist Hospital
Omaha, NE

and Good Samaritan Cancer Center, Kearney, NE

Ovarian  Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? (GOG 0225)  III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Ovarian A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND #70177), versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary
Peritoneal, or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy (GOG 0212)
 III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Ovarian  A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive,
Recurrent Ovarian, Peritoneal, Primary and Fallopian Tube Cancer, NCI-Supplied Agents: Bevacizumab (GOG 0213)
 III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Ovarian A Randomized Phase II Study of NCI Supplied Cabozantinib Versus Weekly Paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GOG 0186-K)  II Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
 Ovarian  A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy (GOG 212) NCI Version: 08/18/11  III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Pamela Nielsen
 The Nebraska Medical Center, Omaha NE
Clear Cell Ovary A Phase II Evaluation of Temsirolimus (CCI-779) in Combination with Carboplatin
and Paclitaxel Followed by Temsirolimus Consolidation as First-line Therapy in the
Treatment of Clear Cell Carcinoma of the Ovary (GOG 0268)
 II Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Clear Cell Ovary A Phase II Evaluation of SU11248 (Sunitinib Malate) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma (GOG 0254)  II Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Sex Cord- Stomal Ovary  A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent
Chemonaive Sex Cord-Stromal Tumors of the Ovary (GOG 0264)
  Kathryn Bartz R
kathryn.bartz@nmhs.org
402-354-7939
 Nebraska Methodist Hospital
Omaha, NE
Mucinous Ovary  A GCIC Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (GOG 0241)   Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Carcinosarcoma A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent
Carcinosarcoma of the Uterus (GOG 0130-F)
 II Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
Carcinosarcoma A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus
Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary GOG 0261)
 III Kathryn Bartz RN
kathryn.bartz@nmhs.org
402-354-7939
Nebraska Methodist Hospital
Omaha, NE
 Other   A Randomized Phase lll Trial with Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage l-lV Persistent and Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum, or Ovary (GOG 0261) (NCI Version Date 09/20/2012)  III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Pamela Nielsen
 The Nebraska Medical Center, Omaha NE

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software